Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Locally Advanced Triple-Negative Breast Cancer
NCT00817531Phase 2Terminated
- Sponsor
- Baylor Breast Care Center
- Start
- Dec 2008
- Primary completion
- Feb 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in triple-negative breast cancer (TNBC), sponsored by Baylor Breast Care Center. Started Dec 2008; status: terminated.
02
Drugs
dasatinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00817531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00817531.